Ipsen SA (IPN) - Total Liabilities
Based on the latest financial reports, Ipsen SA (IPN) has total liabilities worth €2.60 Billion EUR (≈ $3.04 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Ipsen SA to assess how effectively this company generates cash.
Ipsen SA - Total Liabilities Trend (2002–2024)
This chart illustrates how Ipsen SA's total liabilities have evolved over time, based on quarterly financial data. Check IPN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Ipsen SA Competitors by Total Liabilities
The table below lists competitors of Ipsen SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Clorox Company
NYSE:CLX
|
USA | $5.58 Billion |
|
Skanska AB (publ)
ST:SKA-B
|
Sweden | Skr96.34 Billion |
|
Aramark Holdings
NYSE:ARMK
|
USA | $10.31 Billion |
|
Trade Desk Inc
NASDAQ:TTD
|
USA | $3.67 Billion |
|
Yangzijiang Shipbuilding (Holdings) Ltd
F:B8O
|
Germany | €26.08 Billion |
|
Texas Roadhouse Inc
NASDAQ:TXRH
|
USA | $1.79 Billion |
|
Itaúsa - Investimentos Itaú SA
SA:ITSA3
|
Brazil | R$16.57 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Ipsen SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ipsen SA (IPN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ipsen SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ipsen SA (2002–2024)
The table below shows the annual total liabilities of Ipsen SA from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.26 Billion ≈ $2.64 Billion |
-9.68% |
| 2023-12-31 | €2.50 Billion ≈ $2.92 Billion |
+10.03% |
| 2022-12-31 | €2.27 Billion ≈ $2.66 Billion |
+0.82% |
| 2021-12-31 | €2.25 Billion ≈ $2.63 Billion |
+3.38% |
| 2020-12-31 | €2.18 Billion ≈ $2.55 Billion |
-14.68% |
| 2019-12-31 | €2.55 Billion ≈ $2.99 Billion |
+66.49% |
| 2018-12-31 | €1.53 Billion ≈ $1.79 Billion |
-0.14% |
| 2017-12-31 | €1.54 Billion ≈ $1.80 Billion |
+44.74% |
| 2016-12-31 | €1.06 Billion ≈ $1.24 Billion |
+48.98% |
| 2015-12-31 | €712.40 Million ≈ $832.87 Million |
+10.38% |
| 2014-12-31 | €645.40 Million ≈ $754.54 Million |
+9.09% |
| 2013-12-31 | €591.60 Million ≈ $691.64 Million |
-6.81% |
| 2012-12-31 | €634.84 Million ≈ $742.19 Million |
+2.73% |
| 2011-12-31 | €617.97 Million ≈ $722.47 Million |
+3.17% |
| 2010-12-31 | €598.96 Million ≈ $700.25 Million |
+1.09% |
| 2009-12-31 | €592.52 Million ≈ $692.72 Million |
-15.52% |
| 2008-12-31 | €701.36 Million ≈ $819.96 Million |
+34.41% |
| 2007-12-31 | €521.81 Million ≈ $610.05 Million |
+7.29% |
| 2006-12-31 | €486.37 Million ≈ $568.62 Million |
+51.32% |
| 2005-12-31 | €321.41 Million ≈ $375.76 Million |
-23.83% |
| 2004-12-31 | €421.98 Million ≈ $493.34 Million |
+19.12% |
| 2003-12-31 | €354.24 Million ≈ $414.15 Million |
-18.45% |
| 2002-12-31 | €434.38 Million ≈ $507.83 Million |
-- |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more